Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.75 |
| ▸ | DYRK1B | Q9Y463 | 15/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10321335 | 1.00 | DYRK1A (0.75) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10318156 | 1.00 | DYRK1A (0.75) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10318154 | 0.95 | DYRK1A (0.68) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10318152 | 0.95 | DYRK1A (0.68) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10320707 | 0.93 | DYRK1A (0.77) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10323242 | 0.89 | DYRK1A (0.59) | DYRK1ADYRK1B | |
| SCHEMBL10318259 | 0.88 | DYRK1A (0.74) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10379227 | 0.87 | DYRK1A (0.88) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10380135 | 0.87 | DYRK1A (0.88) | DYRK1ADYRK1BTAS1R3TAS1R1 | |
| SCHEMBL10380483 | 0.87 | DYRK1A (0.88) | DYRK1ADYRK1BTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
| US-4352696-A | Process and composition | THE UPJOHN COMPANY (US) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | GOT1, PPARG, PPARA | DYRK1A 2480/4885DYRK1B 3023/4885TAS1R3 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.